MRD in multiple myeloma: the clinical perspective

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Minimal residual disease (MRD) is a critical prognostic indicator in multiple myeloma (MM).
• Conventional complete remission assessments are insufficient for precise treatment efficacy evaluation.
• High-sensitivity assays are essential for detecting low levels of residual disease.

Purpose of the Study:

• To review current methods for detecting minimal residual disease (MRD) in multiple myeloma (MM).
• To discuss the interpretation of MRD assessment in the context of clinical trials.
• To explore how MRD can guide future treatment strategies in MM.

Main Methods:

• Utilizing high-sensitivity techniques such as next-generation flow cytometry (NGF) and next-generation sequencing (NGS).
• Employing allele-specific oligonucleotide quantitative PCR for MRD detection.
• Analyzing data from pivotal clinical trials involving MRD assessment.

Main Results:

• Achieving MRD negativity is consistently linked to improved progression-free survival (PFS) and overall survival (OS).
• MRD negativity is recognized as a validated surrogate of clinical benefit by regulatory bodies.
• MRD detection levels range from 10^-5 to 10^-6.

Conclusions:

• MRD assessment provides a more accurate evaluation of treatment efficacy in MM.
• MRD negativity is a strong predictor of favorable long-term outcomes in multiple myeloma.
• Integrating MRD assessment into clinical practice offers a framework for personalized MM treatment strategies.